Program
Benzydamine
Also written as “benzydamine HCl”, “Benzydamine Hydrochloride 0.15% w/v oromucosal solution” and “Benzydamine Hydrochloride 0.15% Oral Rinse”.
Its studies are mostly in Stomatitis · Head and Neck Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angelini Pharma | 20 open or running | phase 4since Jun 23, 2021 | Jun 23, 2021 | none ahead |
| E2Bio Life Sciences | 11 open or running | phase 2since Apr 11, 2022 | Apr 11, 2022 | none ahead |
| Johnson & Johnson | 10 open or running | phase 3since Jan 9, 2003 | Jan 9, 2003 | none ahead |
Also a collaborator on its studies: cross-research-s-a, ppd-development-lp and angelini.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2003First study: phase 3 study in StomatitisNew to Johnson & JohnsonJohnson & Johnson · NCT00051441 · 605 enrolled
- Jun 23, 2021Angelini Pharma's first study: phase 4 study in Head and Neck NeoplasmsNew to Angelini PharmaAngelini Pharma · NCT05055726 · 100 enrolled · Hungary, Poland
- Apr 11, 2022E2Bio Life Sciences's first study: phase 2 study in StomatitisNew to E2Bio Life SciencesE2Bio Life Sciences · NCT05338398 · 100 planned · Armenia
- Sep 9, 2025Phase 1 study in Healthy VolunteersAngelini Pharma · NCT07199543 · 120 enrolled · Switzerland
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07199543Healthy Volunteers · Switzerland | 1 | Completed | Angelini Pharma | Jul 20, 2025 | 120 |
| NCT05338398Stomatitis · Armenia | 2 | By invitation | E2Bio Life Sciences | Oct 30, 2023 | 100 |
| NCT05055726Head and Neck Neoplasms · Hungary, Poland | 4 | Completed | Angelini Pharma | Sep 5, 2022 | 100 |
| NCT00051441Stomatitis | 3 | Completed | Johnson & Johnson | 605 |
How it is read
Names in the registry
- “benzydamine HCl”, 1 entry
- “Benzydamine”, 1 entry
- “Benzydamine Hydrochloride 0.15% w/v oromucosal solution”, 1 entry
- “Benzydamine Hydrochloride 0.15% Oral Rinse”, 1 entry
Conditions, from the studies’ own filings
- Stomatitis, 2 studies
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.